Each of these companies is experiencing double-digit year-over-year sales growth.

Bitcoin has potential, so do Ethereum, Monero, and all the others, but ASML has even more as the monopoly underpinning the whole tech industry.

Both companies are leaders in their industry, but face a fast-changing landscape.

Wall Street is bullish on these two fintech stocks.

Tesla shareholders have earned every penny of the monster gains registered over the past decade.

Sunrun delivers residential solar and battery storage solutions to U.S. homeowners through a direct-to-consumer model.

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

AI stocks have had a bad 2026 so far.

After a rough Q4 FY 2025 earnings, Ralliant's stock has reached an all-time low. Yet, one of the company's board directors purchased insider shares after the underwhelming earnings.

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

This global beverage company had a strong run in 2025, and now, its stock is set to join one of the top funds in the market.

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

There's good news and bad news for investors right now.

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

The world's largest publisher of children's books is buying back a large swath of its shares.